Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study
International Journal of Rheumatic Diseases · 2024
DOI: 10.1111/1756-185x.15320 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von А Е Karateev und 8 weiteren Autor:innen. Beteiligte Einrichtung: V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Pain Measurement, Chronic Pain, Antirheumatic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: JSC R-Pharm, Russia.
Themen: Schmerzmanagement
Abstract (Originalsprache)
Aim
Evaluate the efficacy and safety ® (olokizumab) in patients with rheumatoid arthritis (RA) in real‐world clinical practice, with a targeted assessment of patient report outcomes (PRO) and central sensitization.
Methods
An open‐label observational non‐interventional study was conducted, enrolling 183 patients with moderate and severe RA activity. All patients received OKZ 64 mg SC as injections every 4 weeks (Q4W) with methotrexate. The patients' follow‐up period was 24 weeks or less. RA activity (DAS28‐CRP), pain severity (NRS), patient global assessment (PGA, NRS), functional impairment (NRS), fatigue (FACIT‐F), central sensitization (central sensitization inventory, CSI), and symptoms of neuropathic pain (PainDETECT) were evaluated.
Results
The study cohort was comprised of 144 patients. And 39 patients were lost to follow‐up, refused OKZ treatment, or were not dosed with OKZ for administrative reasons. In 6 months, DAS28‐CRP decreased to 3.3 ± 0.9 ( p < .001) and statistically significant reductions in pain intensity, PGA, functional impairment, and fatigue were achieved. Pain intensity decreased as early as 2 days after the first OKZ administration ( p < .05). The number of patients with CSI >40 in 24 weeks decreased from 71.0% to 21.0% ( p < .001), with PainDETECT >18 – from 21.5% to 13.2%. NSAIDs use decreased from 70.8% to 33.8% ( р < .001), steroids – from 54.2% to 32.6%. AEs were reported in 14.2% patients, serious events were observed in three patients.
Conclusion
OKZ is effective in reducing RA activity and controlling chronic pain related to dysfunction of the nociceptive system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation.
- Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation.
- Yaroslavl State Medical University, Ministry of Health of the Russian Federation, Yaroslavl, Russian Federation.
- Department of Rheumatology, Kazakh National Medical University named after Asfendiyarov S, Almaty, Russian Federation.
ORCID-Profile: А Е Karateev, Е Y Polishchuk, Е S Filatova, V N Amirdzhanova, V N Khlaboshina, А М Lila, A A Baranov, N A Lapkina, G A Togizbayev
Förderung
- JSC R-Pharm, Russia
Zitieren
APA
Karateev, А. Е., Polishchuk, Е. Y., Filatova, Е. S., Amirdzhanova, V. N., Khlaboshina, V. N., Lila, А. М., Baranov, A. A., Lapkina, N. A., & Togizbayev, G. A. (2024). Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.15320
Vancouver
Karateev АЕ, Polishchuk ЕY, Filatova ЕS, Amirdzhanova VN, Khlaboshina VN, Lila АМ, et al. Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.15320
BibTeX
@article{Karateev2024,
author = {Karateev, А Е and Polishchuk, Е Y and Filatova, Е S and Amirdzhanova, V N and Khlaboshina, V N and Lila, А М and Baranov, A A and Lapkina, N A and Togizbayev, G A},
title = {Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study},
journal = {International Journal of Rheumatic Diseases},
year = {2024},
doi = {10.1111/1756-185x.15320}
}
EUVIMED